Evolus Reports Q4 EPS of $0, Projects FY Sales of $327M-$337M
Summary
Evolus, Inc. announced its fourth-quarter results, reporting earnings per share of $0 and a net income of $130 thousand on product revenue of $89.216 million. The company also provided full-year sales guidance for $327 million to $337 million. This is a critical update for investors as quarterly earnings and forward guidance significantly influence valuation and future expectations. Traders will be assessing these figures against analyst consensus to determine the immediate market reaction and adjust positions accordingly. The low net income and $0 EPS indicate minimal profitability for the quarter.
At the time of this announcement, EOLS was trading at $4.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $267.7M. The 52-week trading range was $4.09 to $14.94. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.